Corvus Pharmaceuticals CRVS Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Arcus BiosciencesRCUS

——

Nektar TherapeuticsNKTR

——

Kymera TherapeuticsKYMR

——

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Corvus Pharmaceuticals's available for sale securities debt securities current?: Corvus Pharmaceuticals (CRVS) reported available for sale securities debt securities current of $196.61M in Q1 2026.